Sorrento Therapeutics (LTS:0L85) Other Current Assets: $10.10 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0L85 Sorrento Therapeutics Inc LTS:0L85
12 GF Score
Price $0.00
View Full Analysis

What is Sorrento Therapeutics Other Current Assets?

Sorrento Therapeutics LTS:0L85 12 Other Current Assets is $10.10 Mil as of Jun. 2023. GuruFocus rates LTS:0L85 with a GF Score™ of 12/100.

Sorrento Therapeutics's other current assets for the quarter that ended in Jun. 2023 was $10.10 Mil.

Sorrento Therapeutics's quarterly other current assets increased from Dec. 2022 ($11.95 Mil) to Mar. 2023 ($12.61 Mil) but then declined from Mar. 2023 ($12.61 Mil) to Jun. 2023 ($10.10Mil).

Sorrento Therapeutics's annual other current assets increased from Dec. 2020 ($12.43 Mil) to Dec. 2021 ($19.29 Mil) declined from Dec. 2021 ($19.29 Mil) to Dec. 2022 ($11.95 Mil).


Sorrento Therapeutics Other Current Assets Related Terms


Sorrento Therapeutics Other Current Assets Historical Data

* Premium members only.

The historical data trend for Sorrento Therapeutics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics Other Current Assets Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.57 27.25 12.43 19.29 11.95

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.03 16.95 11.95 12.61 10.10
LTS:0L85
12GF Score
Sorrento Therapeutics Inc LTS:0L85
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sorrento Therapeutics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $10.10 Mil mean?
Sorrento Therapeutics (LTS:0L85) has a Other Current Assets of $10.10 Mil as of Jun. 2023. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sorrento Therapeutics.
Is Sorrento Therapeutics' Other Current Assets too high?
Sorrento Therapeutics' current Other Current Assets is $10.10 Mil. Overall, Sorrento Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sorrento Therapeutics' Other Current Assets compare to IMUX and OCUP?
Sorrento Therapeutics' Other Current Assets of $10.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sorrento Therapeutics. Sorrento Therapeutics's current Other Current Assets is $10.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sorrento Therapeutics stock overvalued right now?
Sorrento Therapeutics (LTS:0L85) has a current Other Current Assets of $10.10 Mil. The current Other Current Assets is $10.10 Mil. Sorrento Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Sorrento Therapeutics (LTS:0L85), the current Other Current Assets is $10.10 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sorrento Therapeutics Business Description

Address 4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
12GF Score

Get the complete analysis for LTS:0L85

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price